Giridhar Prashanth, Mallick Supriya, Kashyap Lakhan, Rath Goura Kishor
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821. doi: 10.1007/s00405-018-4882-y. Epub 2018 Jan 22.
NUT midline carcinoma is a rare tumour occurring in young adults which is frequently misdiagnosed as poorly differentiated squamous cell carcinoma or germ cell tumour. Though considered highly aggressive, there is limited information about the clinical behaviour of such patients. We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes.
Two authors independently searched PubMed and Google search for eligible studies from 1950 till July 1 2017 published in English language using MESH terms NUT midline carcinoma; NUT midline carcinoma and radiotherapy and translocation 15:19 tumour.
Data of 119 patients were retrieved from 64 publications for statistical analysis. Median age of the entire cohort was 23 years (range 0-68 years). The analysis revealed equal incidence in males and females (60:58). The present analysis revealed that the most common location is the lung (n = 42) followed by head and neck (n = 40). Median OS for the entire cohort was only 5 months with 1 and 5 year OS for the entire cohort was 24.99 and 7.09% respectively. Radiotherapy and chemotherapy inclusion in primary treatment had a significant impact on overall survival on univariate analysis while surgery did not affect survival significantly. No impact on overall survival was found based on type of molecular translocation, i.e., NUT-BRD4, NUT-BRD3 or other variants. Inadequate data were available for identify impact of BET inhibitors and HiDAc on PFS and OS.
NUT midline carcinoma has dismal prognosis. Radiotherapy and chemotherapy improves survival, but do not provide long term control except in anecdotal cases. Further research is needed to improve outcomes in future.
NUT中线癌是一种发生于年轻人的罕见肿瘤,常被误诊为低分化鳞状细胞癌或生殖细胞肿瘤。尽管被认为具有高度侵袭性,但关于这类患者临床行为的信息有限。我们旨在对已发表的文献进行综述,以评估其人口统计学特征、治疗模式并评估生存结果。
两位作者独立检索了PubMed和谷歌搜索,以查找1950年至2017年7月1日期间以英文发表的符合条件的研究,使用医学主题词NUT中线癌;NUT中线癌与放疗及15:19易位肿瘤。
从64篇出版物中检索到119例患者的数据进行统计分析。整个队列的中位年龄为23岁(范围0 - 68岁)。分析显示男性和女性发病率相等(60:58)。目前的分析表明,最常见的部位是肺(n = 42),其次是头颈部(n = 40)。整个队列的中位总生存期仅为5个月,整个队列1年和5年总生存率分别为24.99%和7.09%。单因素分析显示,在初始治疗中纳入放疗和化疗对总生存有显著影响,而手术对生存无显著影响。基于分子易位类型,即NUT - BRD4、NUT - BRD3或其他变体,未发现对总生存有影响。关于BET抑制剂和组蛋白去乙酰化酶抑制剂对无进展生存期和总生存期的影响,可获得的数据不足。
NUT中线癌预后不佳。放疗和化疗可提高生存率,但除个别病例外,无法提供长期控制。未来需要进一步研究以改善治疗结果。